Changes of tau profiles in brains of the hamsters infected with scrapie strains 263 K or 139 A possibly associated with the alteration of phosphate kinases
© Wang et al; licensee BioMed Central Ltd. 2010
Received: 30 March 2009
Accepted: 1 April 2010
Published: 1 April 2010
Phospho-tau deposition has been described in a rare genetic human prion disease, Gerstmann-Sträussler-Scheinker syndrome, but is not common neuropathological picture for other human and animal transmissible spongiform encephalopathies (TSEs). This study investigated the possible changes of tau and phosphorylated tau (p-tau, at Ser396, Ser404, and Ser202/Thr205) in scrapie experimental animals.
The profiles of tau and p-tau (p-tau, at Ser396, Ser404, and Ser202/Thr205) in the brain tissues of agents 263K- or 139A-infected hamsters were evaluated by Western blots and real-time PCR. Meanwhile, the transcriptional and expressive levels of GSK3β and CDK5 in the brains were tested.
The contents of total tau and p-tau at Ser202/Thr205 increased, but p-tau at Ser396 and Ser404 decreased at the terminal stages, regardless of scrapie strains. Transcriptional levels of two tau isoforms were also increased. Additionally, it showed higher CDK5, but lower GSK3β transcriptional and expressive levels in the brains of scrapie-infected animals. Analysis of brain samples collected from different times after inoculated with agent 263 K revealed that the changes of tau profiles and phosphate kinases were time-relative events.
These data suggest that changes of profiles of p-tau at Ser396, Ser404 and Ser202/Thr205 are illness-correlative phenomena in TSEs, which may arise of the alteration of phosphate kinases. Alteration of tau, p-tau (Ser396, Ser404, and Ser202/Thr205), GSK3β and CDK5 were either intermediate or consequent events in TSE pathogenesis and proposed the potential linkage of these bioactive proteins with the pathogenesis of prion diseases.
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs) are a group of fatal neurodegenerative diseases of animals and humans causing severe spongiform degeneration and neuronal loss in central nervous system (CNS). This relatively diverse group includes bovine spongiform encephalopathy in cattle (BSE), scrapie in sheep and goat, chronic wasting disease (CWD) in deer and elk, and kuru, Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI) and Gerstmann-Sträussler-Scheinker (GSS) disease in humans [1, 2]. Clinically, prion diseases can exhibit sporadic, inherited, or infectious presentations. Regardless of the primary etiology, the central event in the pathogenesis is the conformational conversion from the cellular prion protein (PrPC) into its insoluble and protease-resistant forms (termed PrPSc) that accumulate in CNS .
The microtubule-associated protein tau, is a group of molecular mass of 45-66 kDa proteins encoded by alternative splicing of a single gene . There are six predominant tau isoforms in human brain containing 352-441 amino acids . Hyperphosphorylated tau aggregated into paired helical filaments, which is the main component of neurofibrillary tangles found in the brains of Alzheimer's disease (AD) patients . The main aberrantly hyperphosphorylated sites on tau include the phospho-sites Ser-202/Thr-205 (AT8 site), Ser-214 and/or Ser-212 (AT100 site), Thr-231 and/or Ser-235 (TG3 site), and Ser-396/Ser-404 (PHF-1 site) . Precise regulation of phosphorylation of tau is probably important for its normal cellular functions and aberrant tau phosphorylation is believed to disrupt cellular processes such as axonal transport .
The normal phosphorylation state of tau is balanced by antagonistic kinase and phosphatase activity. Some kinases and phosphatases have been implicated in the abnormal hyperphosphorylation of tau . The proline-directed Serine/Threonine kinases, cyclin-dependent kinase 5 (CDK5) and glycogen synthase kinase 3β (GSK3β) have been identified as prime candidates mediating aberrant tau phosphorylation at disease-associated sites . CDK5 co-localizes with filamentous tau deposits and has increased activity in several tauopathies, such as AD . GSK3β generates disease associated phospho-epitopes on tau  and co-localizes with aggregates of hyperphosphorylated tau . Obtained data show that apoptotic neuronal death caused by PrP106-126 is in part due to CDK5 deregulation, causing tau hyperhosphorylation at Ser202/Thr205 and apoptotic death. The inhibitors of CDK5 and calpain reverted tau hyperphosphorylation and prevented neuronal death caused by PrP106-126 . Over-activation of CDK5 in young transgenic animals does not induce tau hyperphosphorylation at sites recognized by the antibodies AT8, AT100, PHF-1 and TG3, while increased GSK3β activity coincides with tau hyperphosphorylation at the AT8 and PHF-1 sites, which reveales the role of GSK3β as a key mediator of tau hyperphosphorylation, whereas CDK5 acts as a modulator of tau hyperphosphorylation via the inhibitory regulation of GSK3β . Both GSK3β and CDK5 can phosphorylate tau at many positions, e.g. Thr181, Ser199, Ser202, Thr205, Thr212, Thr217, Ser396, and Ser404. However, GSK3β seems to prefer phosphorylating tau at its microtubule binding domains in the C-terminus, while CDK5 tends to target the N-terminus .
Human prion diseases share some clinical and neuropathological features with AD. Both are dementia disorders, whose pathogeneses are related to the deposition of abnormal proteins in the extracellular space of the brain and this change is considered to have a crucial role in causing the degeneration and death of neuronal cells. On the other hand, the two diseases have distinct natural processes. CJD is a unique transmissible encephalopathy and the clinical course is much shorter than AD. In sporadic CJD, PrPSc builds up in the gray matter mostly in diffuse form and tau pathology is not considered part of the neuropathological picture . Although there are some reports about Alzheimer-type changes in CJD patients [15, 16], these cases are elder patients, in which neurofibrillary changes are associated with Aβ deposits, likely representing the co-occurrence of CJD with AD or age-related phenomena. In the brain tissues of GSS, a familial prion disease caused by specific mutations of the PrP gene (PRNP), abundant hyperphosphorylated tau (p-tau) depositions have been documented . To date, phospho-tau-related changes have been rarely reported in patients with vCJD [18, 19], but one study describes that phospho-tau often clusters around PrP amyloid deposits in the brains of five vCJD patients and the mouse models of vCJD . Besides, hyperphosphorylation of tau protein has been previously reported in bovine PrP transgenic mice infected with BSE .
In the present study, the relative quantity of total tau protein and its phosphorylated status at Ser396, Ser404, and Ser202/Thr205 in the brain tissues of the hamsters infected with scrapie agent 263 K or 139 A at their clinical terminal stages were evaluated. Western blots revealed that the amounts of total tau and p-tau at Ser202/Thr205 increased, but the levels of p-tau at Ser396 and Ser404 decreased. Transcription of two tau isoforms was also increased. In parallel, the expression and transcription of GSK3β were depressed, while those of CDK5 were increased in the brains of scrapie-infected animals.
Animal brain samples infected with scrapie agents
Five Chinese golden hamsters inoculated intracerebrally with hamster-adapted scrapie agent 263 K and five hamsters inoculated intracerebrally with mouse-adapted scrapie agent 139 A were included in this study. Previously studies confirmed that the incubation time of 263K-infected hamsters was 79.1 ± 8.6 days , while that of 139A-infected hamsters was 395 ± 8.5 days . The brains were removed surgically within 8 hrs after natural death or at the moribund stage. The brains were immediately dissected, then frozen and stored at -80°C until use. Besides, two brain samples of the agent 263K-infected hamsters at the 20th, 40th, 50th, 60th and 70th days after inoculation were collected. Besides, eight normal hamsters were enrolled as controls.
Preparation of brain tissue samples
Brain homogenates of the hamsters were prepared described previously , with slight modification. Brain samples from the scrapie-infected and healthy hamsters were washed in TBS (10 mM Tris HCl, 133 mM NaCl, pH 7.4) for three times, and then 10% (W/V) brain homogenates were prepared in lysis buffer (100 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 10 mM Tris, pH 7.5) containing a mixture of protease inhibitors. The tissue debris was removed by low-speed centrifugation at 2,000 g for 10 min and the supernatants were used for further experiments.
Protease Resistance Assay
For detection of PrPSc in brain tissues, all tested brain homogenates were digested with a final concentration of 50 μg/ml proteinase K (PK) at 37°C for 60 min prior to Western blot, digestion was terminated by addition of PMSF to a final concentration of 5 mM and boiling in SDS-PAGE sample buffer.
Anti-tau monoclonal antibody (mAb) tau13, and anti-β-actin mAb were purchased from Santa Cruz Biotechnology. Anti-PrP mAb 3F4 was purchased from Dako. Anti-p-tau (Ser396) polyclonal antibody (pAb) TAU [pS396], Anti-p-tau (Ser404) pAb TAU [pS404], Anti-GSK3β mAb, and Anti-CDK5 mAb were purchased from Biosource. Anti-p-tau (Ser202/Thr205) mAb AT8 was purchased from Pierce Endogen.
Western blot analysis
Samples were separated by 15% SDS-PAGE and electroblotted onto a nitrocellulose membrane using a semi-dry blotting system (Bio-rad). Membranes were blocked with 5% (w/v) non-fat milk powder (NFMP) in 1 × Tris-buffered saline containing 0.1% Tween 20 (NFMP-TBST) at room temperature for 1 h and probed with mAb 3F4 (1:5000), mAb tau13 (1:4000), pAb TAU [pS396] (1:1000), pAb TAU [pS404] (1:1000), mAb AT8 (1:4000), anti-GSK3β mAb (1:4000), Anti-CDK5 mAb (1:4000) and anti-β-actin mAb (1:2000) at 4°C overnight, respectively. After washing three times with TBST, blots were incubated in HRP-conjugated secondary antibody solutions, 1:5,000-diluted HRP-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (Santa Cruz, CA, USA), at room temperature for 2 h. Blots were developed using Enhanced ChemoLuminescence system (ECL, Amersham Life Sciences, Buckinghamshire, UK) and visualized on autoradiography films.
Real Time Reverse Transcription PCR
Total RNA from the brain of normal and scrapie-infected hamsters were extracted using the TRIzol (Invitrogen) reagent according to the manufacturer's instructions. Reverse transcription was performed using SuperScript™ III First-Strand Synthesis System (Invitrogen). Briefly, 2 μg of total RNA was mixed with 200 U of MMLV reverse transcriptase and 50 pM oligo (dT20) in a volume of 20 μl. The mixtures were maintained at 50°C for 50 min and inactivated by heating at 85°C for 5 min. To remove the RNA from the cDNA, 1 μl E. coli RNase H was added to the mixture and incubated at 37°C for 20 min. Aliquots (2 μl) of RT reaction products were amplified by PCR. The primers used were designed and synthesized according to the published literatures. Since no respective hamster's data available in GenBank, the primers were based on the individual sequences of mouse, including the primers for tau, Tau2-sence 5'-TCG CCA GGA GTT TGA CAC AAT GGA-3', Tau4-sence, 5'-CCA CAC GGA GAT CCC AGA AGG AAT TA-3' and Tau- antisence, 5'-ATT TCC TGT CCT GTC TTT GCT GGC-3' ; Tau6-sence 5'- TAC ACC ATG CAC CAA GAC CA-3' and Tau6-antisence 5'-GTC TCC AAT GCC TGC TTC TT-3 ; GSK3β-sence 5'-CTA AGG ATT CGT CAG GAA CAG-3' and GSK3β-antisence 5'-TTG AGT GGT GAA GTT GAA GAG-3 ; CDK5-sence 5'-ACTGTGTTCAAGGCTAAAAACC-3' and CDK5-antisence 5'-CAATTTCAACTCCCCATTCC-3' ; β-actin-sence 5'-CTA CAA TGA GCT GCG TGT GGC-3' and β-actin-antisence 5'-CAG GTC CAG ACG CAG GAT GGC-3' . Real time-PCR was performed using a supermix containing the fluorescent dye SYBR green (Applied Biosystems) as described previously , briefly, 1 μl of reverse transcription product, 12.5 μl of 2× SYBR Green PCR Master Mix, 1 μl of each primer (10 μM) and 9.5 μl H2O were mixed in a total volume of 25 μl. PCR was performed on a 7500 Fast Real-Time PCR System (Applied Biosystems), under following condition 94°C for 15 s, 55°C for 30 s, and 72°C for 30 s, total 40 cycles. The increases in fluorescence were collected and the expressive level of each specific mRNA was determined relative to that of the individual β-actin. All real time-PCR reactions were performed in triplicate.
Quantitative and statistical analysis
Quantitative analysis of immunoblot images was carried out using Image Total Tech software (Pharmacia). Briefly, the image of immunoblot was scanned with Typhoon (Pharmacia) and digitalized, saved in TIF format. The values of each target blot were evaluated. All data are presented as the mean ± SD. Student's unpaired t test for comparison of means was used to compare groups. Differences were considered significant at a P value < 0.05.
This study was approved by the Ethical Committee of National Institute for Viral Disease Prevention and Control, China CDC.
Increase of total tau in the brain tissues of the scrapie-infected hamsters
To address the presences of PrPSc in the brain tissues of scrapie-infected animals, 10% brain homogenates of five strain 263K- and five 139A-infected hamsters were digested by PK and analyzed with PrP specific Western blots. Three PK-resistant PrP bands were identified in all infected samples, which moved at the position from Mr. 21 to 27 kDa (Figure 1), representing di-, mono- and aglycosal forms.
More active transcription of tau mRNA in the brain tissues of the infected hamsters
Changes of phosphorylated tau profiles in the brain tissues of the scrapie-infected hamsters
To see the difference in the patterns of tau phosphorylation, all brain homogenates were screened by the Western blots with various p-tau-specific antibodies, including pAb TAU [pS396], pAb TAU [pS404] and mAb AT8, which recognize the tau proteins phosphorylated at Serine 396, Serine 404 and Serine 202/Thr 205, respectively. Antibody TAU [pS396] and TAU [pS404] revealed the same reactive profiles that the signal intensities in the hamsters infected with agent 263 K or 139 A were obviously lower than that of normal ones (Figure 4A). Scanning the image of each blots identified the mean relative quantities of p-tau (Ser396 and Ser404) in the infected hamsters were remarkably lower than that in the control group (P < 0.001, Figure 3).
Lower level of GSK3β and higher level of CDK5 in the brain tissues of the scrapie-infected hamsters
Changes of tau profiles and phosphate kinases are time-relative events
AD, the most common form of dementia, is pathologically characterized by Aβ-amyloid plaques and neurofibrillary tangles . The amyloid cascade hypothesis implies that the extracellular deposition of Aβ is the initial and seminal event of AD pathogenesis and the intraneuronal formation of neurofibrillary changes, composed of hyperphosphorylated tau protein, is a consequence of it. In prion disease, a consistent subset of GSS patients, such as some with the most common P102L PRNP mutation, has been shown to harbor neurofibrillary changes further suggesting that tau pathology is downstream from the extracellular deposition of amyloid, either made up of Aβ or PrP . But this has been partially questioned by the fact that in most cases of human prion diseases, the deposition of abnormal PrP in the brain does not induce a tauopathy.
In this study, Western blot and real-time PCR provide the evidences of higher level of tau protein in the brain homogenates of scrapie-infected hamsters. Increased tau protein probably reflects neuronal, preferentially axonal damage or degeneration. Although the scrapie hamster-adapted agent 263 K and agent 139 A bear distinctly different incubation times , the similar increased brain tau at the terminal stages indicates a common phenomenon of scrapie experimental animals, neither related with scrapie strains nor incubation periods.
The phosphorylating status of tau is crucial for its biological activities. Aberrant tau phosphorylation can disrupt axonal transport, which has been proposed as an underlying mechanism possibly giving rise to neurodegeneration . Tau mutants, with serine/threonine targets of GSK3 mutated to glutamate to mimic a permanent state of phosphorylation, are transported at a significantly increased rate compared to wild-type tau. Conversely, tau mutants, in which alanine replaced serine/threonine to mimic permanent dephosphorylation, are transported at a decreased rate compared to wild-type tau . The diverse phosphorylating statuses of tau have been also described in human prion diseases, e.g. increased p-tau in GSS but not in sporadic CJD. Compared with healthy hamsters, inoculations of two scrapie strains into experimental hamsters cause decreased of p-tau at Ser396/Ser404 and increased of p-tau at Ser202/Thr205 in the brains. Tau protein has a series of potential phosphorylating sites, among them only p-tau at Ser396, Ser404 and Ser202/Thr205 has been addressed in this study. One might speculate there are other profiles of p-tau in the brains of human and animal TSEs. However, highly depressed p-tau at Ser396/Ser404 and markedly raised p-tau at Ser202/Thr205 in brains of the hamsters infected by scrapie strongly indicate these changes of p-tau profiles are TSE related events.
CDK5 and GSK3β have been identified as major candidates mediating tau phosphorylation at sites characteristic for neurodegenerative tauopathies. Specific inhibition of GSK3β reduces tau phosphorylation and significantly decreases the overall rate of axonal transport of tau in rat cortical neurons . Alterations of the patterns of other phosphorylation kinase, e.g. CK2 and its subunits, have been also observed in the brain tissues of the experimental and naturally-occurred animal and human TSEs . In this study, we have firstly described that the cerebral level of GSK3β declines and that of CDK5 increases during scrapie pathogenicity. It is reasonable to speculate that the changes of p-tau profiles in the brains of TSEs may link with the alternations of protein kinases.
Our data reveal that the changes of tau profiles and phosphate kinases in scrapie-infected hamsters are time-relative events. In line with the previous observations of PrPSc deposition and neuropathological abnormality, changes of tau and kinases in brains of scrapie experimental animals appear much earlier than the onset of clinical manifestations. Moreover, gradually declined GSK3β and raised CDK5 levels correspond well with the decrease of p-tau (Ser396 and Ser404) and increase of p-tau (Ser202/Thr205), respectively. These phenomena may highlight the possibility that the increase of p-tau (Ser202/Thr205) is due to the higher level of CDK5 and depression of p-tau (Ser396 and Ser404) owes to the lower level of GSK3β. Additionally, GSK3β and CDK5 seems to show individual tropism on phosphorylating tau, which GSK-3β prefers to act on tau at the C-terminus and CDK5 tends to target the N-terminus . The catalytic characteristics of these two kinases on tau may help to explain the special p-tau profiles in scrapie-infected hamsters. Further immunohistochemistry assays for evaluating the alterations of these biofactors in brains assays for illustrating potential pathological characteristics of tau in scrapie will help to clarify the pathogenesis of prion disease.
Our results suggest that changes of profiles of p-tau at Ser396, Ser404 and Ser202/Thr205 are illness-correlative phenomena in TSEs, which may arise of the alteration of phosphate kinases. Alterations of tau and kinases in the brains of TSE animals during pathogenicity may consist of a complicate network. It is still unclear when and how these components function and impact each other. Except for the deposits of PrPSc as the initiative agent, alterations of these bioactive proteins are either intermediate or consequent events in TSE pathogenicity and proposed the potential linkage of these bioactive proteins with the pathogenesis of prion diseases.
This work was supported by Chinese National Natural Science Foundation Grants 30771914 and 30800975, National Science and Technology Task Force Project (2006BAD06A13-2), Institution Technique R&D Grant (2008EG150300), National Basic Research Program of China (973 Program) (2007CB310505), China Mega-Project for Infectious Disease (2009ZX10004-101) and the SKLID development Grant (2008SKLID102 and 2008SKLID202).
- Prusiner SB: Prions. Proc Natl Acad Sci. 1998, 95: 13363-13383. 10.1073/pnas.95.23.13363.View ArticlePubMedPubMed CentralGoogle Scholar
- Collinge J: Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci. 2001, 24: 519-550. 10.1146/annurev.neuro.24.1.519.View ArticlePubMedGoogle Scholar
- Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA: Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron. 1989, 3: 519-526. 10.1016/0896-6273(89)90210-9.View ArticlePubMedGoogle Scholar
- Chun W, Johnson GV: The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci. 2007, 12: 733-756. 10.2741/2097.View ArticlePubMedGoogle Scholar
- Goedert M: Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 1993, 16: 460-465. 10.1016/0166-2236(93)90078-Z.View ArticlePubMedGoogle Scholar
- Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR: Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000, 33: 95-130. 10.1016/S0165-0173(00)00019-9.View ArticlePubMedGoogle Scholar
- Plattner F, Angelo M, Giese KP: The roles of cyclin-dependent kinase5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem. 2006, 281: 25457-25465. 10.1074/jbc.M603469200.View ArticlePubMedGoogle Scholar
- Paudel HK, Lew J, Ali Z, Wang JH: Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J Biol Chem. 1993, 268: 23512-23518.PubMedGoogle Scholar
- Shelton SB, Johnson GV: Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem. 2004, 88: 1313-1326. 10.1111/j.1471-4159.2003.02328.x.View ArticlePubMedGoogle Scholar
- Nishimura I, Yang Y, Lu B: PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell. 2004, 116: 671-682. 10.1016/S0092-8674(04)00170-9.View ArticlePubMedGoogle Scholar
- Ishizawa T, Sahara N, Ishiguro K, Kersh J, McGowan E, Lewis J, Hutton M, Dickson DW, Yen SH: Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol. 2003, 163: 1057-1067.View ArticlePubMedPubMed CentralGoogle Scholar
- Lopes JP, Oliveira CR, Agostinho P: Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies. Cell Mol Neurobiol. 2007, 27: 943-57. 10.1007/s10571-007-9224-3.View ArticlePubMedGoogle Scholar
- Liu F, Iqbal K, Grundke-Iqbal I, Gong CX: Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett. 2002, 530: 209-214. 10.1016/S0014-5793(02)03487-7.View ArticlePubMedGoogle Scholar
- Budka H, Head MW, Ironside JW, Gambetti P, Parchi P, Zeidler M, Tagliavini F: Sporadic Creutzfeldt-Jakob disease in: Dickson, D.(Ed.), neurodegeneration: the molecular pathology of dementia and movement disorders. 2003, ISN Neuropath Press, Basel, Switzerland, 287-297.Google Scholar
- Brown P, Jannotta F, Gibbs CJ, Baron H, Guiroy DC, Gajdusek DC: Coexistence of Creutzfeldt-Jakob disease and Alzheimer's disease in the same patient. Neurology. 1990, 40: 226-228.View ArticlePubMedGoogle Scholar
- Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H: Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol. 1998, 96: 116-122. 10.1007/s004010050870.View ArticlePubMedGoogle Scholar
- Ghetti B, Piccardo P, Frangione B, Bugiani O, Giaccone G, Young K, Prelli F, Farlow MR, Dlouhy SR, Tagliavini F: Prion protein amyloidosis. Brain Pathol. 1996, 6: 127-145. 10.1111/j.1750-3639.1996.tb00796.x.View ArticlePubMedGoogle Scholar
- Ironside JW, Head MW, McCardle L, Knight R: Neuropathology of variant Creutzfeldt-Jakob disease. Acta Neurobiol. 2002, 62: 175-182.Google Scholar
- Streichenberger N, Jordan D, Verejan I, Souchier C, Philippeau F, Gros E, Mottolese C, Ostrowsky K, Perret-Liaudet A, Laplanche JL, Hermier M, Deslys JP, Chazot G, Kopp N: The first case of new variant Creutzfeldt-Jakob disease in France: clinical data and neuropathological fndings. Acta Neuropathol. 2000, 99: 704-708. 10.1007/s004010051184.View ArticlePubMedGoogle Scholar
- Giaccone G, Mangieri M, Capobianco R, Limido L, Hauw JJ, Haïk S, Fociani P, Bugiani O, Tagliavini F: Tauopathy in human and experimental variant Creutzfeldt-Jakob disease. Neurobiol Aging. 2008, 29: 1864-1873. 10.1016/j.neurobiolaging.2007.04.026.View ArticlePubMedGoogle Scholar
- Bautista MJ, Gutiérrez J, Salguero FJ, Fernández de Marco MM, Romero-Trevejo JL, Gómez-Villamandos JC: BSE infection in bovine PrP transgenic mice leads to hyperphosphorylation of tau protein. Vet Microbiol. 2006, 115: 293-301. 10.1016/j.vetmic.2006.02.017.View ArticlePubMedGoogle Scholar
- Zhang J, Chen L, Zhang BY, Han J, Xiao XL, Tian HY, Li BL, Gao C, Gao JM, Zhou XB, Ma GP, Liu Y, Xu CM, Dong XP: Comparison study on clinical and neuropathological characteristics of hamsters inoculated with scrapie strain 263 K in different challenging pathways. Biomed Environ Sci. 2004, 17: 65-78.PubMedGoogle Scholar
- Zhang BYHX, Gao C, Gao JM, Zhou XB, Hong T, Dong XP: Mouse-adapted scrapie strain 139 A can overcome species barrier to induce spongiform encephalopathy in golden hamster. Chin J Virol. 2002, 18: 337-341. (in Chinese)Google Scholar
- Yao HL, Han J, Gao JM, Zhang J, Zhang BY, Guo YJ, Nie K, Gao C, Wang XF, Dong XP: Comparative study of the effects of several chemical and physical treatments on the activity of protease resistance and infectivity of scrapie strain 263 K. J Vet Med B Infect Dis Vet Public Health. 2005, 52: 437-433.View ArticlePubMedGoogle Scholar
- Sergeant N, Sablonnière B, Schraen-Maschke S, Ghestem A, Maurage CA, Wattez A, Vermersch P, Delacourte A: Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet. 2001, 10: 2143-2155. 10.1093/hmg/10.19.2143.View ArticlePubMedGoogle Scholar
- Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C: Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 in prostate cells. J Biol Chem. 2004, 279: 32444-32452. 10.1074/jbc.M313963200.View ArticlePubMedGoogle Scholar
- Lena Lilja, Shao-Nian Yang, Dominic-Luc Webb, Lisa Juntti-Berggren, Per-Olof Berggren, Christina Bark: Cyclin-dependent Kinase 5 Promotes Insulin Exocytosis. J Biol Chem. 2001, 276: 34199-34205. 10.1074/jbc.M103776200.View ArticleGoogle Scholar
- Bayatti N, Zschocke J, Behl C: Brain region-specific neuroprotective action and signaling of corticotropin-releasing hormone in primary neurons. Endocrinology. 2003, 144: 4051-4060. 10.1210/en.2003-0168.View ArticlePubMedGoogle Scholar
- Nishimura M, Naito S: Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2008, 23: 22-44. 10.2133/dmpk.23.22.View ArticlePubMedGoogle Scholar
- Ishizawa K, Komori T, Shimazu T, Yamamoto T, Kitamoto T, Shimazu K, Hirose T: Hyperphosphorylated tau deposits parallels prion protein burden in a case of Gerstmann-Straussler-Scheinkersyn drome P102L mutation complicated with dementia. Acta Neuropathol. 2002, 104: 342-350.PubMedGoogle Scholar
- Chen JM, Gao C, Shi Q, Shan B, Lei YJ, Dong CF, An R, Wang GR, Zhang BY, Han J, Dong XP: Different expression patterns of CK2 subunits in the brains of experimental animals and patients with transmissible spongiform encephalopathies. Arch Virol. 2008, 153: 1013-1020. 10.1007/s00705-008-0084-z.View ArticlePubMedGoogle Scholar
- Cuchillo-Ibanez I, Seereeram A, Byers HL, Leung KY, Ward MA, Anderton BH, Hanger DP: Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J. 2008, 22: 3186-3195. 10.1096/fj.08-109181.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/10/86/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.